



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)
 Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24
 E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 31.03.2011

Particulars	Quarter	Quarter	12 Months	Rs. in lacs
	ended 31.03.2011 Unaudited	Ended 31.03.2010 Unaudited	Ended 31.03.2011 Unaudited	ended 31.03.2010 Audited
1a Net sales/Income from Operations	3185.05	3957.77	16095.02	13959.34
1b Other Operating Income				
Total	3185.05	3957.77	16095.02	13959.34
2 Expenditure				
a. (Inc.)/Dec. in Stock in trade & work in progress	-643.34	-230.66	192.46	-1042.09
b. Consumption of Raw Materials	2091.41	2430.37	7143.54	7219.40
c. Purchase of traded goods	161.06	20.01	963.95	1372.92
d. Employees Cost	750.13	600.41	3222.70	2378.78
e. Depreciation	45.35	50.01	211.80	208.50
f. Other Expenditure	699.62	652.31	3147.55	2458.50
g. Total	3104.23	3522.45	14882.00	12596.01
3 Profit from Operations before Other Income, Interest and	80.82	435.32	1213.02	1363.33
4 Other Income	25.31	29.89	25.31	36.30
5 Profit before Interest and Exceptional items (3+4)	106.13	465.21	1238.33	1399.63
6 Interest	50.65	84.34	332.11	349.62
7 Profit after Interest but before Exceptional Items (5-6)	55.48	380.87	906.22	1050.01
8 Exceptional Items				
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	55.48	380.87	906.22	1050.01
10 Tax expense	16.50	24.69	188.50	125.81
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	38.98	356.18	717.72	924.20
12 Extraordinary Items (net of tax expense)				
13 Net Profit(+)/Loss(-) for the period(11-12)	38.98	356.18	717.72	924.20
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance				6049.30
16 Earnings Per Share (EPS)				
a. Basic & diluted EPS before extraordinary items for the period.	0.15	1.36	2.74	3.53
b. Basic & diluted EPS after extraordinary items for the	0.15	1.36	2.74	3.53
17 Public shareholding :				
- Number of shares	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding				
A Pledged / encumbered				
- Number of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of	-	-	-	-
- Percentage of shares (as a % of the total share capital of	-	-	-	-
B Non - encumbered				
- Number of shares	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of	65.79%	65.79%	65.79%	65.79%

Notes

- The Financial Results for the Quarter ended 31.03.2011 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 13-5-2011
- No complaints were pending at the beginning/end of the quarter ended 31.03.2011. However 45 requests for change of address/ dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.

Place : New Delhi
 Date : 13.5.2011



By Order of the Board
 For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
 Managing Director